Viz.ai has once again set a benchmark in AI-powered healthcare innovation by earning its third consecutive Edison Award™ in 2025, solidifying its leadership in machine learning for cardiovascular diagnostics.
Revolutionizing Cardiac Care with the Viz HCM Module
The award-winning solution, Viz HCM, is an advanced AI tool tailored to detect and manage hypertrophic cardiomyopathy (HCM), a frequently overlooked hereditary heart condition. Leveraging machine learning, the system analyzes 12-lead electrocardiograms (ECGs) across healthcare networks to flag potential HCM cases, alert cardiology teams, and streamline patient diagnostics and care pathways.
According to recent insights shared at the American College of Cardiology, the Viz HCM module was instrumental in identifying 574 HCM patients in just nine months at a prestigious institution, the Cleveland Clinic. This showcases its remarkable potential in enhancing early detection and timely intervention for at-risk patients.
Industry Recognition and Regulatory Milestones
The Edison Awards, named after famed inventor Thomas Edison, are considered one of the most prestigious honors for innovation and product development. Viz HCM secured its spot in the Health Medical & Biotech category, under the Cardiovascular Health Diagnostics and Monitoring subcategory. This accolade reflects its significant contribution to smarter, faster, and more accurate disease management.
Additionally, the Viz HCM module received De Novo approval by the FDA in August 2023, a milestone that established a new regulatory category specifically for cardiovascular machine learning-based notification systems. This not only validates the technology’s effectiveness but also paves the way for broader adoption in clinical environments.
Partnering for Progress
This breakthrough was developed through a long-term collaboration between Viz.ai and Bristol Myers Squibb (NYSE:BMY), focusing on leveraging AI to optimize patient outcomes. Through this partnership, Viz.ai continues to push boundaries and redefine what’s possible in AI-powered diagnostics.
For those exploring the next frontier in intelligent healthcare, Viz.ai’s success story aligns with broader trends in the AI-medical landscape, such as the growing investments in quantum-AI innovations for critical sectors.
Award Judging and Industry Impact
Entries for the Edison Awards are meticulously reviewed by a steering committee and a panel of over 2,000 senior executives, academics, and past winners from fields including science, engineering, marketing, and education. Winners were officially announced during the Edison Awards Gala held on April 3, 2025, in Fort Myers, Florida.
Viz.ai’s continued recognition underscores the transformative power of AI in healthcare and the potential it holds to improve diagnostic workflows, reduce time to treatment, and ultimately save lives.
To learn more about Viz HCM and its capabilities, visit the official Viz.ai page: https://www.viz.ai/hypertrophic-cardiomyopathy.
